NCT00915408已完成1 期
A Phase I Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
King's College Hospital NHS Trust2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Safety (type, frequency, severity, and relationship of adverse events)
研究概览
简要总结
The purpose of this study is to determine the maximum tolerated dose (MTD) and to evaluate the safety of cyclophosphamide when given on days 1 and 8 in a 28 day cycle in doses starting at 300mg ranging to 700mg in combination with Lenalidomide (Revlimid®) plus dexamethasone in patients who present with relapsed or refractory myeloma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign an informed consent form.
- •Age >18 years at the time of signing the informed consent form.
- •Proven diagnosis of multiple myeloma.
- •Relapse or Refractory disease with evidence of progression after at least 2 cycles of anti-myeloma treatment.
- •Relapse or refractory disease with evidence of progressive disease after at least 1 previous therapy this may include consolidation of induction with a stem cell transplant).
- •Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) must be complete prior to the initiation of therapy. The initiation of radiation therapy after baseline (Day 1) will be considered to be a treatment failure (except when given to treat or to promote the healing of a pathological fracture).
- •Measurable levels of myeloma paraprotein in serum (>5 gms/L) or urine > 2 g excreted in a 24-hour collection sample).
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or
- •Able to adhere to the study visit schedule and other protocol requirements.
- •Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 10 - 14 days and again within 24 hours of starting study drug. In addition, sexually active WCBP must agree continued abstinence from heterosexual intercourse or to use adequate contraceptive methods starting 4 weeks prior to the initiation of therapy. WCBP must agree to have pregnancy tests weekly for the first 4 weeks, then monthly while on study drug (every 14 days for women with irregular cycles) and 4 weeks after the last dose of study drug. Men must also agree to use a condom if their partner is of child bearing potential, even if they have had a successful vasectomy.
- •Disease free of prior malignancies for equal to or over 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast.
- •Able to receive low dose aspirin (e.g. 75mg) as prophylactic anticoagulant medication to prevent thromboembolism unless contraindicated. If low dose aspirin is contraindicated, subjects will receive another form of anticoagulant prophylaxis according to hospital guidelines.
排除标准
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or lactating females.
- •Any of the following laboratory abnormalities:
- •Absolute neutrophil count (ANC) <1.000 cells/mm3 (1.0 x 109/L)
- •Platelet count <.75.000/mm3 (75 x 109L)
- •Serum creatinine >2.5 mg/dL (221 umol/L)
- •Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)
- •Serum total bilirubin >2.0 mg/dL (34 umol/L)
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Known hypersensitivity to thalidomide, dexamethasone or cyclophosphamide.
- •Prior history of uncontrollable side effects to dexamethasone therapy
- •The development of a desquamating rash while taking thalidomide
- •Any prior use of Lenalidomide (Revlimid®)
- •Use of any standard/experimental anti-myeloma drug therapy within 28 days of entry or use of any experimental non-drug therapy (e.g. donor leukocyte/mononuclear cell infusions) within 56 days of entry.
研究组 & 干预措施
CRD
Experimental
干预措施: Lenalidomide (Drug)
CRD
Experimental
干预措施: Dexamethasone (Drug)
CRD
Experimental
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Safety (type, frequency, severity, and relationship of adverse events)
时间窗: Weekly for first cycle then monthly
Dose limiting toxicity defined as: a) NCI Grade 4 haematological toxicity b) NCI Grade ¾ non-haematological toxicity
时间窗: Weekly for first cycle
次要结局
- Paraprotein response(Monthly)
- Time to progression(Monthly)
- Bone marrow response(Baseline, end of treatment and disease progression)
- Duration of response(Monthly)
- Overall survival(Monthly)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid TumorsSolid TumorsNCT01357330Sanofi18
终止
1 期
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Solid TumorsNCT04564417Pierre Fabre Medicament33
已完成
1 期
A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.Refractory or Recurrent CD30+ Hematologic MalignanciesNCT03894150Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.45
已完成
1 期
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36
终止
1 期
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid TumorNeoplasms, MalignantNCT01001221Sanofi19